IMRX Earnings Date 2026
Immuneering Corp earnings schedule and quarterly results
Next Earnings Date
TBD
Current Stock Price
$4.91
+1.13% today
Earnings Metrics
EPS (TTM)
$-1.79
P/E Ratio
-2.6
Revenue Growth
-99.8%
Market Cap
$0.1B
Earnings History
| Quarter | EPS | Revenue | Net Income |
|---|---|---|---|
| Q4 2024 | $-2.04 | - | $-0.06B |
| Q4 2023 | $-1.88 | - | $-0.05B |
Trading Around IMRX Earnings
Before Earnings
- Review analyst expectations and consensus estimates
- Check options implied volatility for expected move
- Consider historical earnings surprises
- Monitor pre-announcement guidance
After Earnings
- Compare actual results to estimates
- Listen to the earnings call for guidance
- Watch for analyst rating changes
- Monitor institutional buying/selling
Get Full IMRX Analysis
DCF valuation, AI insights, and institutional ownership data
Frequently Asked Questions
When is IMRX next earnings date?
IMRX (Immuneering Corp) has not yet announced its next earnings date. Check back for updates on the upcoming earnings schedule.
What is IMRX earnings per share (EPS)?
IMRX's current earnings per share (EPS) is $-1.79. With a P/E ratio of -2.6, the market values each dollar of earnings at $-2.6.
How often does IMRX report earnings?
Like most publicly traded US companies, IMRX (Immuneering Corp) reports earnings quarterly, typically within 4-6 weeks after each fiscal quarter ends. The company holds an earnings call to discuss results with analysts.
What time does IMRX report earnings?
IMRX typically reports earnings either before market open (BMO) or after market close (AMC). The exact time is usually announced a few days before the earnings date. Check the investor relations page for specific timing.
How has IMRX performed in recent earnings?
In the most recent quarter (Q4 2024), IMRX reported EPS of $-2.04.
What do analysts expect for IMRX earnings?
Analyst expectations for IMRX earnings can vary. The company has shown negative revenue growth of -99.8%. View the full analyst ratings page for detailed expectations.